返回 Agenda
Session 9BC: Expanding Therapeutic Utility via Targeted Delivery
Session Chair(s)
Patrik Andersson, PhD
Senior Director, RNA Therapeutics Safety
AstraZeneca R&D, Sweden
This joint preclinical/clinical session will present novel translational insights of GalNAc-conjugated ASOs as well as novel targeting strategies for increasing productive uptake into cell types that normally are challenging to reach with oligonucleotide therapeutics. These include muscle and immune cells as well as pancreatic islets. The presentations will be followed by a 30 minute panel discussion. Discussion topics include:
Learning Objective : Recognize the opportunities and challenges of developing novel targeting approaches
Speaker(s)
Session Co-Chair
Sree Rayavarapu, DVM, PhD
FDA, United States
Toxicologist
Translational Development of a GalNAC-Conjugated LNA-Based Single Stranded Oligonucleotide
Wouter Driessen, PhD, MS
F. Hoffmann-La Roche AG, Switzerland
DMPK Project Leader
Oligonucleotide Therapeutics Now on Target
Arthur A. Levin, PhD
Avidity Biosciences, United States
Distinguished Scientist
Targeting Antisense Oligonucleotides to Pancreatic Islets
Patrik Andersson, PhD
AstraZeneca R&D, Sweden
Senior Director, RNA Therapeutics Safety
Panel Discussion
All Session Speakers, United States